Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pembrolizumab endorsed as melanoma therapy by NICE

NICE recommends pembrolizumab to treat melanoma


Patients with advanced melanoma should have the option of pembrolizumab therapy, says the National Institute for Health and Care Excellence

Pembrolizumab (Keytruda) has been recommended for use as a melanoma treatment in England by the National Institute for Health and Care Excellence (NICE).

The drug can be used for adult patients with melanoma that has spread or cannot be completely removed by surgery despite treatment with ipilimumab and, for BRAF V600 mutation‑positive disease, treatment with a BRAF or MEK inhibitor.

Pembrolizumab, developed by Merck Sharp & Dohme, acts on the programmed cell death protein‑1 immune checkpoint receptor pathway, allowing reactivation of anti-tumour immunity. The humanised monoclonal antibody was previously available in the UK through the early access to medicines scheme.

The drug is a “great example” of progress being made with immune treatments for cancer, says Peter Johnson from Cancer Research UK. “We’re pleased that NICE has acted quickly to make it available on the NHS.”

The announcement from NICE on 7 October 2015 follows the approval of pembrolizumab by the US Food and Drug Administration (FDA) for the treatment of some patients with advanced non-small cell lung cancer.

The US medicines safety watchdog fast-tracked pembrolizumab’s approval and stipulates that it must be used in conjunction with a diagnostic test that detects expression of the PD-L1 protein in non-small cell lung tumours.

Prembrolizumab was designated a break-through therapy by the FDA for this indication because it could offer “substantial” improvements to patients compared with other therapies.

The drug was approved by the FDA for the treatment of patients with advanced melanoma in 2014.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069495

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • NICE recommends pembrolizumab to treat melanoma

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.